ARTV Key Statistics, Chart & Performance
The current stock price of ARTV is 4.855 USD. In the past month the price increased by 58.14%. In the past year, price decreased by -48.07%.
ARTV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About ARTV
Company Profile
Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. The company is headquartered in San Diego, California and currently employs 106 full-time employees. The company went IPO on 2024-07-19. The firm is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Company Info
ARTIVA BIOTHERAPEUTICS INC
5505 Morehouse Drive
San Diego CALIFORNIA US
Employees: 106
Phone: 18582674467
ARTIVA BIOTHERAPEUTICS INC / ARTV FAQ
What does ARTIVA BIOTHERAPEUTICS INC do?
Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. The company is headquartered in San Diego, California and currently employs 106 full-time employees. The company went IPO on 2024-07-19. The firm is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Can you provide the latest stock price for ARTIVA BIOTHERAPEUTICS INC?
The current stock price of ARTV is 4.855 USD. The price increased by 6% in the last trading session.
Does ARTV stock pay dividends?
ARTV does not pay a dividend.
How is the ChartMill rating for ARTIVA BIOTHERAPEUTICS INC?
ARTV has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting ARTV stock to perform?
12 analysts have analysed ARTV and the average price target is 17.34 USD. This implies a price increase of 257.16% is expected in the next year compared to the current price of 4.855.
Is ARTIVA BIOTHERAPEUTICS INC (ARTV) expected to grow?
The Revenue of ARTIVA BIOTHERAPEUTICS INC (ARTV) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for ARTIVA BIOTHERAPEUTICS INC?
ARTIVA BIOTHERAPEUTICS INC (ARTV) currently has 106 employees.
ARTV Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ARTV. When comparing the yearly performance of all stocks, ARTV turns out to be only a medium performer in the overall market: it outperformed 66.84% of all stocks.
ARTV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARTV. No worries on liquidiy or solvency for ARTV as it has an excellent financial health rating, but there are worries on the profitability.
ARTV Financial Highlights
Over the last trailing twelve months ARTV reported a non-GAAP Earnings per Share(EPS) of -3.24. The EPS increased by 7.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.2% | ||
| ROE | -61.28% | ||
| Debt/Equity | 0 |
ARTV Forecast & Estimates
12 analysts have analysed ARTV and the average price target is 17.34 USD. This implies a price increase of 257.16% is expected in the next year compared to the current price of 4.855.
For the next year, analysts expect an EPS growth of 35.88% and a revenue growth -100% for ARTV